NASDAQ:ARGX argenex Q1 2026 Earnings Results & Report $825.03 +6.40 (+0.78%) Closing price 04:00 PM EasternExtended Trading$817.50 -7.53 (-0.91%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. argenex reported Q1 2026 earnings on March 31, 2026. The company reported EPS of $5.52, while revenue was $1.31 billion. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMarch 31, 2026TimeBefore Market Opens argenex EPS ResultsActual EPS$5.52Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersargenex Revenue ResultsActual Revenue$1.31 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile argenex Q1 2026 Earnings FAQ Did argenex beat earnings estimates for Q1 2026? argenex (NASDAQ:ARGX) reported earnings of $5.52 per share for Q1 2026. The report was announced on Tuesday, March 31, 2026. What was argenex's revenue for Q1 2026? argenex reported revenue of $1.31 billion for Q1 2026. argenex Earnings Headlinesargenx: The Sjögren's Selloff Looks OverdoneOctober 9 at 1:41 PM | seekingalpha.comargenx (ENXTBR:ARGX) Gets Mixed Trial News, Is It Still Overvalued?October 9 at 1:41 PM | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 9 at 1:00 AM | Porter & Company (Ad)Argenx Reports Mixed Pipeline Update With Positive Celiac Data; Ends Sjögren's Phase 3 StudyOctober 9 at 3:39 AM | rttnews.comargenx Reports Positive Phase 2 Celiac Disease Trial Results, Plans Phase 3 Development of FB102October 8 at 10:38 PM | finance.yahoo.comARGX stock sinks as Argenx scraps late-stage trialOctober 8 at 10:38 PM | msn.comSee More argenex Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like argenex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on argenex and other key companies, straight to your email. Email Address About argenexargenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders. argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn). They are used in certain patients with generalized myasthenia gravis, and efgartigimod has also received regulatory approvals for chronic inflammatory demyelinating polyneuropathy and other indications in selected markets. Founded in 2008, argenx is headquartered in Ghent, Belgium, with operations and commercial activities in the United States and other international markets. The company continues to develop efgartigimod for additional autoimmune conditions and maintains a broader pipeline of investigational therapies. Tim Van Hauwermeiren serves as chief executive officer.View argenex ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
